UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population

[1]  B. Geramizadeh,et al.  The frequency and distribution of thiopurine S-methyltransferase alleles in south Iranian population , 2012, Molecular Biology Reports.

[2]  N. Hakooz,et al.  Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole , 2012, Molecular Biology Reports.

[3]  B. Gridelli,et al.  Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. , 2011, International journal of molecular medicine.

[4]  I. Djaffar-Jureidini,et al.  Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population. , 2011, Genetic testing and molecular biomarkers.

[5]  N. Azarpira,et al.  Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma , 2011, Molecular Biology Reports.

[6]  N. Hakimé,et al.  Prevalence of CYP2C19 polymorphisms in the Lebanese population , 2011, Molecular Biology Reports.

[7]  X. Zhang,et al.  Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients. , 2010, Transplantation proceedings.

[8]  W. Newman,et al.  Genetic analysis of thiopurine methyltransferase polymorphism in the Jordanian population , 2010, European Journal of Clinical Pharmacology.

[9]  Dongxiao Sun,et al.  Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors , 2010, Drug metabolism reviews.

[10]  C. Jang,et al.  Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects , 2010, European Journal of Clinical Pharmacology.

[11]  C. Guillemette,et al.  A pharmacogenetics study of the human glucuronosyltransferase UGT1A4 , 2009, Pharmacogenetics and genomics.

[12]  S. Pavanello,et al.  CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. , 2009, Life sciences.

[13]  Shufeng Zhou,et al.  Polymorphism of human cytochrome P450 enzymes and its clinical impact , 2009, Drug metabolism reviews.

[14]  C. Guillemette,et al.  Analysis of inherited genetic variations at the UGT1 locus in the French‐Canadian population , 2009, Human mutation.

[15]  Kwang-Hyeon Liu,et al.  Genetic Variations and Haplotypes of UDP-glucuronosyltransferase 1A Locus in a Korean Population , 2008, Therapeutic drug monitoring.

[16]  M. Ingelman-Sundberg,et al.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans , 2007, European Journal of Clinical Pharmacology.

[17]  R. Dellinger,et al.  Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants , 2006, Breast Cancer Research.

[18]  J. Potter,et al.  Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus , 2006, Human mutation.

[19]  K. Muro,et al.  Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. , 2006, Biochemical pharmacology.

[20]  K. K. Kohli,et al.  CYP3A phenotypes and genotypes in North Indians , 2006, European Journal of Clinical Pharmacology.

[21]  N. Saijo,et al.  Haplotype structures of the UGT1A gene complex in a Japanese population , 2006, The Pharmacogenomics Journal.

[22]  C. Guillemette,et al.  Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. , 2005, Pharmacogenetics and genomics.

[23]  A. Mori,et al.  UDP-GLUCURONOSYLTRANSFERASE 1A4 POLYMORPHISMS IN A JAPANESE POPULATION AND KINETICS OF CLOZAPINE GLUCURONIDATION , 2005, Drug Metabolism and Disposition.

[24]  Teruhiko Yoshida,et al.  Genetic variations and haplotypes of UGT1A4 in a Japanese population. , 2005, Drug metabolism and pharmacokinetics.

[25]  M. Manns,et al.  Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP‐glucuronosyltransferase UGT1A4 , 2004, Hepatology.

[26]  Jia-Long Fang,et al.  Correlation between UDP-Glucuronosyltransferase Genotypes and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone Glucuronidation Phenotype in Human Liver Microsomes , 2004, Cancer Research.

[27]  J. Brockmöller,et al.  Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population , 2003, European Journal of Clinical Pharmacology.

[28]  F. Leyva-Cobián,et al.  Molecular analysis of HLA allelic frequencies and haplotypes in Jordanians and comparison with other related populations. , 2001, Human immunology.

[29]  R. Tukey,et al.  Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. , 2001, Molecular pharmacology.

[30]  R. Tukey,et al.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease. , 2000, Annual review of pharmacology and toxicology.

[31]  Robert J. Brooker,et al.  Genetics: Analysis and Principles , 1998 .

[32]  N. Saha,et al.  A genetic study of the Jordanians. , 1981, Human heredity.